SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sagimet Biosciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$8.86+0.84 (+10.47%)
Close on Oct 19, 2026
- Market cap
- $470.59M
- P/E (TTM)
- –
- Dividend yield
- –
Sagimet Biosciences Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -38.2%
Financial strength
- Current ratio
- 45.02
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 3061.4%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.84
- Dividend yield
- –